Table 2 Surveillance for hepatotoxicity during follow-up period among treatment episodes
Drug | Treatment episodes | Cumulative events within 12 months (%) * | Episodes in which any ALT testing occurred during follow - up period | Event rates for hepatotoxicity | ||||
|---|---|---|---|---|---|---|---|---|
0 - 3 month (%) Ϯ | 3 - 6 month (%) Ϯ | 6 - 12 month (%) Ϯ | 0 - 3 month events (% ) Ŧ | 3 - 6 month events (%) Ŧ | 6 - 12 month events (%) Ŧ | |||
Biologic agents | 309 | 8 | 271 | 201 | 179 | 4 | 3 | 1 |
Abatacept | 27 | 2 (7.4) | 24 (88.9) | 21 (77.8) | 18 (66.7) | 0 (0) | 1 (4.8) | 1 (5.6) |
Adalimumab | 116 | 2 (1.7) | 103 (88.8) | 77 (66.4) | 74 (63.8) | 1 (1.0) | 1 (1.3) | 0 (0) |
Etanercept | 113 | 3 (2.7) | 92 (81.4) | 70 (61.9) | 65 (57.5) | 2 (2.2) | 1 (1.4) | 0 (0) |
Infliximab | 29 | 0 (0) | 28 (96.6) | 18 (62.1) | 14 (48.3) | 0 (0) | 0 (0) | 0 (0) |
Rituximab | 24 | 1 (4.2) | 24 (100) | 15 (62.5) | 8 (33.3) | 1 (4.2) | 0 (0) | 0 (0) |
Nonbiologic agents | 650 | 18 | 524 | 373 | 317 | 9 | 4 | 5 |
Leflunomide | 110 | 3 (2.7) | 93 (84.5) | 71 (64.5) | 50 (45.5) | 1 (1.1) | 1 (1.4) | 1 (2.0) |
Methotrexate | 183 | 8 (4.4) | 163 (89.1) | 113 (61.7) | 103 (56.3) | 3 (1.8) | 1 (0.9) | 4 (3.9) |
Sulfasalazine-Hydroxychloroquine | 357 | 7 (2.2) | 268 (75.1) | 189 (52.9) | 164 (45.9) | 5 (1.9) | 2 (1.1) | 0 (0) |
TOTAL (% of total episodes) | 959 | 26 (2.7) | 795 (82.9) | 574 (59.9) | 496 (51.7) | 13 (1.6) | 7 (1.2) | 6 (1.2) |